Abstract
Facial and neck pigmentations are the most cosmetically important. They are common in middle-aged women, and are related to endogenous (hormones) and exogenous factors (such as use of cosmetics and perfumes, and exposure to sun radiation). Melasma (chloasma) is the most common cause of facial pigmentation, but there are many other forms such as Riehl’s melanosis, poikiloderma of Civatte, erythrose peribuccale pigmentaire of Brocq, erythromelanosis follicularis of the face and neck, linea fusca, and cosmetic hyperpigmentations.
Treatment of melasma and other facial pigmentations has always been challenging and discouraging. It is important to avoid exposure to the sun or to ultraviolet lamps, and to use broad-spectrum sunscreens. Several hypopigmenting agents have been used with differing results. Topical hydroquinone 2 to 4% alone or in combination with tretinoin 0.05 to 0.1 % is an established treatment. Topical azelaic acid 15 to 20% can be as efficacious as hydroquinone, but is less of an irritant. Tretinoin is especially useful in treating hyperpigmentation of photoaged skin. Kojic acid, alone or in combination with glycolic acid or hydroquinone, has shown good results, due to its inhibitory action on tyrosinase. Chemical peels are useful to treat melasma: trichloroacetic acid, Jessner’s solution, Unna’s paste, α-hydroxy acid preparations, kojic acid, and salicylic acid, alone or in various combinations have shown good results. In contrast, laser therapies have not produced completely satisfactory results, because they can induce hyperpigmentation and recurrences can occur. New laser approaches could be successful at clearing facial hyperpigmentation in the future.
Similar content being viewed by others
References
Diaz-Pérez J.L., Mitxelena J., Diaz-Ramón L., et al. Discromías. Medicine 1999; 136: 6425–6430
Serrano S., Fernández-Vozmediano J.M. Hiperpigmentaciones por medicamentos. Monogr Dermatol 1996; 9: 45–55
Armijo M., Ortega R.M. Discromías. In: Armijo M., Camacho F., editors. Dermatología. 3rd ed. Madrid: Aula Médica Ed., 1998: 353–380
Kaminsky C.A., Kaminsky A.R. Discromías. Monogr Dermatol 1992; 5: 81–93
Camacho F., Pathak M.A. Hipermelanosis cervicofaciales. Monogr Dermatol 1996; 5: 279–290
Warren F.M., Davis L.S. Erythromelanosis follicularis faciei in women. J Am Acad Dermatol 1995; 32: 863–866
Litt J.Z. Steroid induced rosacea. Am Fam Physician 1993; 48: 67–71
Henmdrix Jr J.D., Greer K.E. Cutaneous hyperpigmentation caused by systemic drugs. Int J Dermatol 1992; 31: 458–466
Hoffmann E., Habermann R. Arzneiliche und gewerbliche Dermatosen durch Kriegsersatzmittel (Vaseline, Schmieröl) und eigenartige Melanodermatiden. Dtsch Med Wochenschr 1918; 44: 261–264
Vazquez M., Maldonado H., Benaman C. et al. Melasma in men; a clinical and histologic study. Int J Dermatol 1988; 27: 25–27
Pandya A.G., Guevara IL. Disorders of hyperpigmentation. Dermatol Clin 2000; 18: 91–98
Katsambas A., Antoniou Ch. Melasma. Classification and treatment. J Eur Acad Dermatol Venereol 1995; 4: 217–223
Pérez N.P., Sánchez J.L., Aquilo F. Endocrinologic profile of patients with idiopathic melasma. J Invest Dermatol 1983; 81: 543–545
Lufti R.J., Fridmanis M., Misrunas A.L. Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of melasma. J Clin Endocrinol Metab 1985; 61: 28–31
Sánchez N.P., Pathak M.A., Sato S., et al. Melasma. A clinical, light microscopic, ultrastructural and immunofluorescence study. J Am Acad Dermatol 1981; 4: 698–710
Palumb A., Dischia M., Misuraca G. Mechanism of inhibition of melanogenesis by hydroquinone. Biochem Biophys Acta 1991; 1073: 85–90
Arndt K.A., Fitzpatrick T.B.: Topical use of hydroquinone as a depigmenting agent. JAMA 1965; 194: 965–967
Snider R.I., Theirs B.H. Exogeneous ochronosis. J Am Acad Dermatol 1993; 28: 662–664
Salopek T.G., Jimbow K. New treatment options for the patient with facial hyperpigmentation. Curr Opin Dermatol 1995; 61–68
Jimbow K. N-acetyl-cysteaminylphenol as a new type of depigmenting agent for the melanoderma of patients with melasma. Arch Dermatol 1991; 127: 1528–1534
Camacho F., Sotillo I., Moreno J.C. Melanoma. Introducción. Inmunoterapia del melanoma con BCG. Acido azelaico como tratamiento complementario del melanoma maligno. Symposium de Inmunología y Dermatología. Madrid: Grupo Jarpyo Ed., 1987: 38–48
Fitton A., Goa K.L. Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 1991; 41: 780–798
Balina L.M., Graupe K. The treatment of melasma 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol 1991; 30: 893–895
Kimbrough-Green C.K., Griffiths C.E., Finkel L.J. Topical retinoic acid (tretinoin) for melasma in black patients. Arch Dermatol 1994; 130: 727–733
Lim J.T. Treatment of melasma using Kojic Acid in a gel containing Hydroquinone and Glycolic Acid. Dermatol Surg 1999; 25: 282–284
Cotellesa C., Peris K., Onorati M.T., et al. The use of chemical peelings of different cutaneous hyperpigmentations. Dermatol Surg 1999; 25: 450–454
Pandya A.G., Guevara I.L. Disorders of hyperpigmentation. Dermatol Clin 2000; 1891–1898
Grimes P.E. The safety and efficacy of salycilic acid chemical peels in darker racial-ethnic groups. Dermatol Surg 1999; 25: 18–22
Gupta G., McKay I.R., McKay R.M. Q-switched ruby laser in the treatment of labial melanotic macules. Lasers Surg Med 1998; 25: 219–222
Manaloto R.S., Alster T. Erbium: YAG Laser resurfacing for refractory Melasma. Dermatol Surg 1999; 25: 121–123
Nouri K., Bowes L., Chartier T., et al. Combination treatment of melasma with pulsed CO2 Lase followed by Q-Switched Alexandrite Laser: a pilot study. Dermatol Surg 1999; 25: 494–497
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pérez-Bernal, A., Muñoz-Pérez, M.A. & Camacho, F. Management of Facial Hyperpigmentation. Am J Clin Dermatol 1, 261–268 (2000). https://doi.org/10.2165/00128071-200001050-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200001050-00001